Blockade of processing/activation of caspase-3 by hypoxia.

Blockade of processing/activation of caspase-3 by hypoxia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Blockade of processing/activation of caspase-3 by hypoxia. Abstract Text:

Tumor hypoxia, which is caused by the rapid proliferation of tumor cells and aberrant vasculature in tumors, results in inadequate supplies of oxygen and nutrients to tumor cells. Paradoxically, these unfavorable growth conditions benefit tumor cell survival, although the mechanism is poorly understood. We have demonstrated for the first time that hypoxia inhibits TRAIL-induced apoptosis by blocking translocation of Bax from cytosol to the mitochondria in tumor cells. However, it is largely unknown how hypoxia-inhibited Bax translocation attenuates TRAIL-induced apoptosis. Here, we demonstrate that despite its inhibitory activity in TRAIL-induced apoptosis, hypoxia does not affect TRAIL-triggered proximal apoptotic signaling events, including caspase-8 activation and Bid cleavage. Instead, hypoxia inhibited processing of caspase-3, leading to incomplete activation of the caspase. Importantly, hypoxia-blocked translocation of Bax to the mitochondria significantly inhibited releasing the mitochondrial factors, such as cytochrome c and Smac/DIABLO, to the cytosol in response to TRAIL. It is well-known that complete processing/activation of caspase-3 requires Smac/DIABLO released from mitochondria. Therefore, our data indicate that an engagement of the apoptotic mitochondrial events leading to caspase-3 activation is blocked by hypoxia. Our data shed new light on understanding of the apoptotic signal transduction and targets regulated by tumor hypoxia.

Blockade of processing/activation of caspase-3 by hypoxia. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Blockade of processing/activation of caspase-3 by hypoxia. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Biochemical and biophysical research communication

VOLUME: 375

Page Numbers: 684-8

Journal Abbreviation:

ISSN: 1090-2104

DAY: 30

MONTH: 08

YEAR: 2008

Blockade of processing/activation of caspase-3 by hypoxia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372516

Blockade of processing/activation of caspase-3 by hypoxia. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Blockade of processing/activation of caspase-3 by hypoxia. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Blockade of processing/activation of caspase-3 by hypoxia.

AFFILIATION: BioNanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology, P.O. Box 115, Yuseong, Daejeon 305-600, Republic of Korea.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Biochem Biophys Res Commun

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Blockade of processing/activation of caspase-3 by hypoxia Related Publications

• Benign ovarian tumors with solid and cystic components that mimic malignancy.
• Blockade of processing/activation of caspase-3 by hypoxia.
• CT findings in Kikuchi disease: analysis of 96 cases.
• Distribution of Conjugative-Plasmid-Mediated 16S rRNA Methylase Genes among Amikacin-Resistant Enterobacteriaceae Isolates Collected in 1995 to 1998 and 2001 to 2006 at a University Hospital in South Korea and Identification of Conjugative Plasmids Mediat
• Effects of anodic oxidation parameters on a modified titanium surface.
• LRRK2 regulates synaptic vesicle endocytosis.
• Nucleotide triphosphates inhibit the degradation of unfolded proteins by HslV peptidase.
• P43.15: Benign ovarian tumors with solid and cystic components that mimic malignancy.
• Specific inhibition of transcriptional activity of the constitutive androstane receptor (CAR) by the splicing factor SF3a3.
• The role of mitochondria in apoptosis.
• [Biliary-duodenal Fistula Following Radiofrequency Ablation Therapy for Hepatocellular Carcinoma.]
• [Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection.]
• [Short-term therapy with pegylated interferon plus ribavirin for the chronic hepatitis C genotype 2 patients]